Diffuse Large B-Cell Lymphoma

Diffuse Large B-Cell Lymphoma

RAS Mediates BET Inhibitor-Endued Repression of Lymphoma Migration and Prognosticates a Novel Proteomics-Based Subgroup of DLBCL Through Its Negative Regulator IQGAP3

Study investigators found that BET inhibitor JQ1 abrogated the amoeboid movement of DLBCL cells through a small GTPase-driven mechanism, including both restrained RAS signaling and...

Polatuzumab Vedotin May Be Effective Salvage or Bridging Therapy for Large B-Cell Lymphomas

Polatuzumab vedotin may be an effective for patients with R/R large B-cell lymphoma as a bridging therapy to CAR T-cell therapy.

Hematology Advisor
Frequent Mutated B2M, EZH2, IRF8, and TNFRSF14 in Primary Bone DLBCL Reflect a GCB Phenotype

These features indicate PB-DLBCL as a distinct extranodal DLBCL entity, and its specific mutations offer potential for targeted therapies.

Blood Advances

Detection of Clonotypic DNA in the Cerebrospinal Fluid as a Marker of Central Nervous System Invasion in Lymphoma

Researchers studied a NGS-based assay that detects tumor-derived DNA for clonotypic immunoglobulin gene rearrangements in the CSF of patients with lymphomas.

Blood Advances
R-NPLD Combination Treatment Safe and Effective for Patients With DLBCL

R-NPLD is an effective and safe combination in patients aged 80 years or older with DLBCL, according to study results presented at the ESMO Congress 2021.

Hematology Advisor
CAR T-Cell Therapies Show Similar Efficacy in R/R DLBCL


A comparative analysis of the CAR T-cell therapies tisagenlecleucel and lisocabtagene maraleucel in patients with R/R DLBCL showed no significant differences in survival outcomes.

Cancer Therapy Advisor
Autologous and Allogeneic Hematopoietic Cell Transplantation for DLBCL–Type Richter Syndrome

This study shows that allo-HCT and auto-HCT produce durable remissions in patients with DLBCL-RS.

Blood Advances
Application of CD54 in Diagnosing Bone Marrow Involvement by Using Flow Cytometry in Patients With Diffuse Large B-Cell Lymphoma

Investigators detected the expression CD54 on lymphoma cells in BM specimens from DLBCL patients...

BMC Cancer
Dimethyl Fumarate Induces Ferroptosis and Impairs NF-κB/STAT3 Signaling in DLBCL

As a result of low glutathione and glutathione peroxidase 4 levels and high 5-lipoxygenase expression, DMF induces ferroptosis in GCB DLBCL.

Molecular Heterogeneity in Localized Diffuse Large B-Cell Lymphoma

Study investigators analyze the clinical characteristics and prognostic features of localized DLBCL both in retrospective and prospective cohorts, and evaluated the molecular heterogeneity between.

Frontiers in Oncology
Assessing and Management of Neurotoxicity After CAR-T Therapy in Diffuse Large B-Cell Lymphoma

CAR-T therapy represents the most important advances in cancer immunotherapy, especially in hematological malignancies such as B-cell lymphomas.

Journal of Blood Medicine
Clinicopathological Features and Survival in EBV+ DLBCL Not Otherwise Specified

In this study, investigators report 70 cases of EBV+ DLBCL not otherwise specified among 1696 DLBCL-NOS cases diagnosed between 2006 and 2019.

Blood Advances
High-Dose Methotrexate is Effective for Prevention of Isolated CNS Relapse in DLBCL

Study investigators evaluate the efficacy of prophylactic HDMTX on isolated CNS relapse, concomitant CNS and systemic relapse, systemic relapse, and survival outcomes...

Blood Cancer Journal
LAG3 and PD1 Regulate CD8+ T Cell in Diffuse Large B-cell Lymphoma Patients

This study is aimed at investigating the potential roles of programmed cell death protein 1 and lymphocyte activation gene 3 in CD8+ T cells for treatment in DLBCL.

Computational and Mathematical Methods in Medicine
Identification of PLA2G7 as a Novel Biomarker of DLBCL

Differentially expressed genes associated with DLBCL were identified using two GEO datasets in an effort to detect novel diagnostic or prognostic biomarkers of this cancer type...

BMC Cancer
Novel Antibody-Drug Conjugate Under Study in Refractory DLBCL

The combination of the CD37-targeting antibody-drug conjugate naratuximab emtansine and rituximab yielded deep and long-lasting responses in patients with R/R DLBCL...

The ASCO Post
KDM5 Inhibition Offers a Novel Therapeutic Strategy for the Treatment of KMT2D Mutant Lymphomas

KDM5 inhibition reverts the effects of KMT2D mutations by increasing levels of H3K4me3 and restoring expression of KMT2D-regulated genes.

Plastin-3 is a Diagnostic and Prognostic Marker for Pancreatic Adenocarcinoma and Distinguishes From DLBCL

This study assessed differentially expressed genes and then bioinformatically and experimentally confirmed PLS3 to be able to predict pancreatic ductal adenocarcinoma prognosis and distinguish...

Cancer Cell International
Impact of Rituximab Biosimilars on Overall Survival in Diffuse Large B-cell Lymphoma

Three-year overall survival did not differ between DLBCL patients treated with rituximab biosimilars and those receiving rituximab originator.

Blood Advances
Genomic Complexity is Associated With Epigenetic Regulator Mutations and Poor Prognosis in DLBCL

In this study, investigators perform targeted next-generation sequencing and fluorescent multiplex immunohistochemistry, and investigate the clinical significance and immunological effect of...

Prognostic Value of Baseline and Interim Positron Emission Tomography Markers in Diffuse Large B-cell Lymphoma Patients

Optimal PET parameters and imaging time points to prognosticate PFS as well as OS of patients with DLBCL have not been established.

Anti-PD-1 Antibodies as a Salvage Therapy for Patients With Diffuse Large B Cell Lymphoma Who Progressed/Relapsed After CART19/20 Therapy

In this study, investigators analyze data from five patients with R/R DLBCL who had disease progression or relapse following CART19/20 therapy and then treated with PD-1-blocking antibodies...

Journal of Hematology & Oncology
Novel Model Shows High Predictive Potential in Patients With DLBCL

A novel model that combines signatures of metabolic dysregulation with clinical features may aid in clinical decision-making among patients with DLBCL, according to research published in the Journa

Hematology Advisor
Polatuzumab Vedotin as a Salvage and Bridging Treatment in Relapsed or Refractory Large B-Cell Lymphomas

Pola is an effective treatment in heavily pretreated patients with r/r LBCL, but long-term remissions are rare.

Blood Advances
Impact of High-Dose Methotrexate on the Outcome of Patients With Diffuse Large B-Cell Lymphoma and Skeletal Involvement

Study investigators analyze the impact of adding high-dose methotrexate to standard chemotherapy on the outcome of patients with DLBCL and skeletal involvement.

Expression and Prognostic Significance of PD-L2 in Diffuse Large B-Cell Lymphoma

Study investigators examine the relationship between PD-L2 expression and clinicopathological features in DLBCL.

Frontiers in Oncology
Whole Transcriptome Data Analysis Reveals Prognostic Signature Genes for Overall Survival Prediction in Diffuse Large B Cell Lymphoma

With the improvement of clinical treatment outcomes in DLBCL, the high rate of relapse in DLBCL patients is still an established barrier, as the therapeutic strategy selection based on...

Frontiers in Genetics
ctDNA and Early Relapse After Axicabtagene Ciloleucel Infusion in Large B-Cell Lymphoma

In a prospective study reported in the Journal of Clinical Oncology, investigators found that monitoring of ctDNA improved detection of early relapse after axicabtagene ciloleucel infusion in patie

The ASCO Post
Phase II Study of Naratuximab Emtansine Plus Rituximab in DLBCL

Adding the antibody-drug conjugate naratuximab emtansine to rituximab results in favorable OS and complete response rates for patients with R/R DLBCL, with a manageable safety profile.

The ASCO Post
The Regulation of miR-320a/XBP1 Axis Through LINC00963 for Endoplasmic Reticulum Stress and Autophagy in Diffuse Large B-Cell Lymphoma

This study incorporates fundamental research referring to considerable amounts of gene-sequencing data and bioinformatics tools to analyze the pathological mechanisms of DLBCL.

Cancer Cell International
Loncastuximab Tesirine in Relapsed or Refractory Diffuse Large B-Cell Lymphoma

Study investigators aim to evaluate the antitumour activity and safety of loncastuximab tesirine in patients with relapsed or refractory DLBCL.

The Lancet Oncology
Value of Total Lesion Glycolysis and Cell-of-Origin Subtypes for Prognostic Stratification of Diffuse Large B-Cell Lymphoma Patients

This study aims to explore the added prognostic value of baseline metabolic volumetric parameters and cell of origin subtypes to the NCCN-IPI in nodal DLBCL patients.

Quantitative Imaging in Medicine and Surgery
Dynamic Changes in Peripheral Blood Lymphocyte Subset Counts and Functions in Patients With Diffuse Large B Cell Lymphoma During Chemotherapy

This study aims to analyze the lymphocyte subsets, their activities and their dynamic changes during immunochemotherapy in patients newly diagnosed with DLBCL.

Cancer Cell International

source list reference

rgb(171, 222, 222)
200, 66, 245
rgb(195, 2, 230)
rgb(209, 15, 15)
rgb(115, 43, 196)
rgb(9, 151, 227)
rgb(242, 0, 137)
rgb(48, 38, 189)
rgb(231, 165, 240)
rgb(230, 21, 49)
rgb(156, 242, 7)
rgb(224, 4, 129)
rgb(80, 147, 199)
rgb(5, 235, 235)
rgb(235, 190, 9)
rgb(209, 227, 11)
200, 66, 245
rgb(217, 7, 192)
rgb(2, 230, 230)